MarginsXMarginsX
Home › Markets › NWBO

Northwest Biotherapeutics Inc (NWBO)

NWBO is quoted over the counter, not listed on an exchange. Northwest Biotherapeutics Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.1462
-8.6% on the day
1-year return
-39.1%
Market cap
$264.9M
Micro cap. From the Nov 16, 2026 close × 1.81B shares (10-Q cover page, Nov 10, 2026)
P/E and P/S
Net loss over the period · 121.9×
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerNWBO, quoted over the counter
SEC CIK0001072379
OTC Markets tierOTCQB (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressBethesda, MD
Incorporated inDE

Warning signs

Cash runway
0.1 months
$595K cash at June 30, 2026
Share count, 1 year
+17.6%
2025-11-13 to 2026-11-10 · +57.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for at least one year from the date of this filing."
10-Q 2026-11-13
Cash and burn$595K cash; operating cash flow -$12.1M a quarter.Report 2026-06-30
Shares outstanding1,811,970,770 (2026-11-10); 1,540,682,082 a year earlier; 1,153,846,907 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2025-11-25
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCherry Bekaert LLP, Nashville, Tennessee, United StatesPCAOB Form AP 2026-04-21
Late filings, 12 months1 NT noticeNT 10-K 2026-03-31
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$807K-$9.2M-$7.2M$595K$52.0M$2.2M10-Q 2026-08-14
Q1 2026
2026-03-31
$494K-$3.1M-$12.5M$1.8M$59.4M$1.5M10-Q 2026-05-15
Q4 2025
2025-12-31
$672K$1.4M-$14.8M$3.0M$60.0M$1.4M10-K 2026-04-15
Q3 2025
2025-09-30
$200K-$26.8M-$13.9M$4.6M$72.2M$937K10-Q 2025-11-14
Q2 2025
2025-06-30
$131K-$15.4M-$6.7M$4.3M$64.7M$1.1M10-Q 2026-08-14
Q1 2025
2025-03-31
$375K-$19.3M-$9.4M$2.8M$64.1M$1.5M10-Q 2026-05-15
Q4 2024
2024-12-31
$231K-$28.2M-$20.2M$2.2M$62.7M$1.4M10-K 2026-04-15
Q3 2024
2024-09-30
$357K-$19.4M-$8.2M$2.9M$53.3M$1.6M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-07-31
Latest annual report10-K2026-04-15
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-10-30
Latest proxyDEF 14A2025-11-28

Source: SEC EDGAR submissions feed, 804 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier